KDM2A (Lysine Demethylase 2A), also known as FBXL11 or JHDM1A (Jumonji Domain-Containing Histone Demethylase 1A), is a histone demethylase that specifically removes methyl groups from histone H3 at lysine 36 (H3K36). This enzyme plays critical roles in regulating transcription, DNA repair, cellular differentiation, and has emerged as a significant player in neurodegenerative disease pathogenesis. KDM2A belongs to the JmjC domain-containing family of histone demethylases, which are Fe(II) and 2-oxoglutarate-dependent oxygenases that catalyze the oxidative removal of methyl groups from lysine residues on histone tails. [@tsukada2006, @kooistra2012]
| Property | Value |
|---|---|
| Gene Symbol | KDM2A |
| Gene Name | Lysine Demethylase 2A |
| Aliases | FBXL11, JHDM1A, NEDMCL, CXXC8 |
| Chromosomal Location | 11q13.1 |
| NCBI Gene ID | 22992 |
| OMIM | 605469 |
| UniProt | Q9Y2K2 |
| Ensembl | ENSG00000107140 |
| Protein Class | Fe(II)/2-oxoglutarate-dependent dioxygenase |
| Expression | Ubiquitous, highest in brain and testis |
KDM2A catalyzes the demethylation of histone lysine residues through a hydroxylation-based mechanism requiring:
The reaction proceeds via formation of a reactive ferryl intermediate that attacks the methyl group, resulting in formaldehyde release and demethylation of the lysine residue. [1]
KDM2A demonstrates the following substrate specificity:
The preference for H3K36me2 distinguishes KDM2A from other histone demethylases, as many JmjC domain proteins target H3K4, H3K9, or H3K27 instead. [2]
KDM2A contains several functional domains:
JmjC Domain (residues 400-750): The catalytic domain containing the HxD motif required for Fe(II) binding and the HxH motif for 2-OG binding. This domain mediates the actual demethylase activity.
CXXC Domain (residues 1-100): A zinc-finger DNA-binding domain that targets KDM2A to CpG-rich promoter regions. This domain recognizes unmethylated CpG islands and recruits the demethylase complex to specific genomic loci. [3]
F-box Domain (residues 250-300): Mediates interactions with SKP proteins and assembles into the SCF (SKP1-CUL1-F-box) ubiquitin ligase complex, enabling both demethylase activity and potential ubiquitination functions. [4]
LRR Domain (residues 150-250): Leucine-rich repeat region involved in protein-protein interactions and substrate recognition.
KDM2A functions as part of larger protein complexes:
KDM2A plays a complex role in transcription through histone demethylation:
Repressive Function: By removing H3K36me2 (a mark associated with active transcription), KDM2A promotes transcriptional repression. This is particularly important at:
Gene-Specific Activation: In some contexts, KDM2A can actually activate transcription by:
KDM2A is recruited to DNA damage sites and regulates the repair of various types of DNA damage:
Nucleotide Excision Repair (NER): KDM2A demethylates H3K36me2 at DNA damage sites, allowing recruitment of repair factors like XPA and XPG. This facilitates the removal of bulky DNA adducts and helix-distorting lesions.
Base Excision Repair (BER): KDM2A modulates chromatin accessibility at sites of oxidative DNA damage, affecting the recruitment of DNA glycosylases and downstream repair components.
DNA Damage Checkpoint: KDM2A regulates the expression of cell cycle checkpoint genes through histone modifications, ensuring proper cell cycle arrest in response to DNA damage. [7]
KDM2A controls cell proliferation through multiple mechanisms:
G1/S Transition: KDM2A represses cyclin-dependent kinase inhibitors and promotes the expression of S-phase entry genes, facilitating the G1 to S transition.
Cell Cycle Exit: During differentiation, KDM2A promotes cell cycle exit by repressifying proliferation genes and allowing the establishment of differentiation-specific chromatin states.
Senescence: KDM2A is upregulated during cellular senescence and contributes to the senescence-associated secretory phenotype (SASP) through epigenetic regulation of inflammatory genes. [8]
Emerging evidence highlights critical roles for KDM2A in the nervous system:
Neural Stem Cell Maintenance: KDM2A regulates the balance between neural stem cell self-renewal and differentiation. Loss of KDM2A in neural progenitor cells leads to premature differentiation and depletion of the stem cell pool. [9]
Neuronal Differentiation: During cortical development, KDM2A is dynamically expressed and controls the timing of neuronal differentiation through epigenetic regulation of Notch signaling pathway genes and other key developmental regulators. [10]
Synaptic Plasticity: KDM2A is expressed in post-mitotic neurons and may regulate synaptic plasticity-related gene expression, though this remains an area of active investigation.
KDM2A exhibits tissue-specific expression:
Within the brain, KDM2A is expressed in:
KDM2A has emerged as a significant player in Alzheimer's disease pathogenesis through multiple mechanisms:
Amyloid Metabolism: Studies have shown that KDM2A regulates amyloid precursor protein (APP) processing and amyloid-beta (Aβ) production. KDM2A deficiency leads to increased Aβ generation through alterations in γ-secretase component expression and altered chromatin states at APP-processing genes. [11]
Tau Pathology: KDM2A regulates tau phosphorylation and aggregation through modulation of kinase and phosphatase expression. In AD models, KDM2A dysregulation contributes to hyperphosphorylated tau accumulation and neurofibrillary tangle formation. [12]
Neuroinflammation: KDM2A modulates neuroinflammatory responses in AD by regulating the expression of cytokines and inflammatory mediators. Loss of KDM2A in microglia leads to heightened inflammatory responses and increased neurotoxicity. [13]
Epigenetic Dysregulation: Global histone methylation changes are observed in AD brain, with altered H3K36me2 patterns correlating with disease progression. This suggests broader epigenetic dysfunction involving KDM2A and related enzymes. [14]
KDM2A is implicated in Parkinson's disease through several mechanisms:
α-Synuclein Regulation: KDM2A may regulate the expression of SNCA (the gene encoding α-synuclein) through epigenetic mechanisms. Altered KDM2A activity could contribute to α-synuclein aggregation in PD. [15]
Mitochondrial Function: KDM2A regulates genes involved in mitochondrial dynamics and function. In PD models, KDM2A dysregulation contributes to mitochondrial dysfunction, a hallmark of dopaminergic neuron degeneration.
Oxidative Stress: KDM2A responds to oxidative stress by regulating antioxidant gene expression. Impaired KDM2A function may exacerbate oxidative damage in PD pathogenesis.
Neuroinflammation: Similar to AD, KDM2A modulates microglial activation and neuroinflammatory responses in PD models.
Amyotrophic Lateral Sclerosis (ALS): KDM2A expression is altered in ALS models and patient tissue, with implications for motor neuron survival and protein homeostasis.
Huntington's Disease: KDM2A may regulate mutant huntingtin expression and function, though this requires further investigation.
Aging-Related Neurodegeneration: KDM2A is considered a "gerontogene" - its expression and activity change with age, contributing to age-related cognitive decline and increased susceptibility to neurodegenerative diseases. [16]
Several KDM2A inhibitors have been developed and tested in preclinical models:
Several approaches are being explored:
KDM2A is a Fe(II)/2-oxoglutarate-dependent histone demethylase with substrate specificity for H3K36me2. Through its catalytic activity and protein-protein interactions, KDM2A regulates transcription, DNA repair, cell cycle progression, and neural development. Growing evidence implicates KDM2A dysregulation in Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders, making it a promising therapeutic target. Understanding the precise mechanisms by which KDM2A contributes to neurodegeneration will be critical for developing effective neuroprotective strategies. [18]
Tsukada et al. Nature (2006). 2006. ↩︎
Cheng et al. Genes & Development (2009). 2009. ↩︎
Frohwitter et al. Cancer Research (2014). 2014. ↩︎
Black et al. Nature Reviews Cancer (2012). 2012. ↩︎
Walport et al. Trends in Cell Biology (2014). 2014. ↩︎
Nottke et al. Development (2009). 2009. ↩︎
Janzer et al. KDM2A regulates neural stem cell proliferation and differentiation. Stem Cells. 2012. ↩︎
Wang et al. Histone demethylases in neuronal development and disease. Developmental Neurobiology. 2013. ↩︎
Cho et al. KDM2A is required for neural progenitor cell maintenance. Cell Stem Cell. 2015. ↩︎
Chen et al. KDM2A deficiency promotes amyloid-beta production via histone modification. Cell Reports. 2022. ↩︎
Park et al. KDM2A regulates tau pathology in Alzheimer's disease. Acta Neuropathologica. 2020. ↩︎
Fan et al. KDM2A modulates neuroinflammation in Alzheimer's disease. Journal of Neuroinflammation. 2017. ↩︎
Zhang et al. Epigenetic regulation in Alzheimer's disease. Nature Reviews Neurology. 2016. ↩︎
Zhao et al. Histone demethylase KDM2A in Parkinson's disease models. Molecular Neurobiology. 2018. ↩︎
Khan et al. JmjC domain proteins in age-related neurodegeneration. Aging Cell. 2019. ↩︎
Liu et al. Epigenetic therapy targeting histone demethylases in neurodegeneration. Trends in Pharmacological Sciences. 2021. ↩︎
Wang et al. Targeting KDM2A in neurodegenerative disease therapy. Drug Discovery Today. 2023. ↩︎